Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Multiple Sclerosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019Multiple Sclerosis Therapeutics Market is Forecast to Show Slow Growth through to 2019
By: Rajesh Gunnam The current MS therapeutics market includes DMDs approved for the management of Relapse-Remitting MS (RRMS) and drugs for symptom management. At present there are no approved drugs for the progressive stages of the disease. The DMDs prescribed for MS include four interferons: The MS therapeutics market is expected to witness slow growth (in terms of CAGR) through the forecast period to 2019 in comparison with the historical period 2006-2011. In 2011, the US accounted for more than half of the global MS therapeutics market. The slow growth in the market is the result of the cumulative effect of both positive and negative factors within the market. The patent expiry of Copaxone (expected US patent expiry 2014 and expected European patent expiry 2015) is expected to negatively impact the US market; Copaxone has a high cost of therapy and has a strong presence in the US market. However, the introduction of pipeline products will neutralize the value erosion of the market, resulting in slow growth through to 2019. Aubagio (teriflunamide) For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ The launch of new pipeline products is expected to change the present market scenario, which is mainly dependant on injectable formulations (such as Avonex, Betaseron/Betaferon, Rebif, Copaxone, and Tysabri). These drugs need to be injected frequently, and their dose frequency ranges from daily to weekly administration. Within the new drugs some are oral formulations (Aubagio and BG-12) and some are injectable formulations (daclizumab, ocrelizumab and alemtuzumab) GlobalData, the industry analysis specialist, has released its new report, “Multiple sclerosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global multiple sclerosis therapeutics market. The report identifies the key trends shaping and driving the global market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global multiple sclerosis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
|